CN-122005675-A - Traditional Chinese medicine probiotics composition for preventing and treating colorectal cancer and application thereof

Abstract

The invention belongs to the field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine probiotic composition for preventing and treating colorectal cancer and application thereof. A traditional Chinese medicine probiotic composition comprises the following raw materials, by mass, 15g of pulsatilla chinensis, 12g of ash bark, 12g of phellodendron bark and 6g of coptis chinensis, and probiotics, wherein the probiotics are bifidobacterium pseudolongum (Bifidobacterium pseudolongum, B.p) with the deposit number of ATCC 25526. The invention discovers that the combined application of the Chinese pulsatilla root decoction compound and the bifidobacterium pseudolongum shows remarkable synergic and excellent effects in the aspect of inhibiting colorectal cancer, is superior to the single application of traditional Chinese medicine compound or probiotics, provides a novel, safe and effective traditional Chinese medicine and traditional Chinese medicine-probiotic combined intervention scheme for preventing and treating colorectal cancer, and has good application prospect.

Inventors

• XU HANCHEN
• JI GUANG
• LU LU
• LI SUMEI
• LI HUAN
• SU HANG
• LI ZONGPING

Assignees

• 上海中医药大学附属龙华医院

Dates

Publication Date

20260512

Application Date

20260211

Claims (7)

1. 1. The traditional Chinese medicine probiotic composition is characterized by comprising a traditional Chinese medicine composition and probiotics; the traditional Chinese medicine composition is prepared from the following raw materials in parts by mass, 15g of pulsatilla chinensis, 12g of cortex fraxini, 12g of cortex phellodendri and 6g of coptis chinensis; the probiotic is bifidobacterium pseudolongum (Bifidobacterium pseudolongum, B.p) deposited under ATCC 25526.
2. 2. The traditional Chinese medicine probiotic composition according to claim 1, characterized in that the administration ratio of said traditional Chinese medicine composition to bifidobacterium pseudolongum is 30-90g/10 9 -10 11 CFU.
3. 3. The traditional Chinese medicine probiotic composition according to claim 2, characterized in that said bifidobacterium pseudolongum is administered at a dose of 10 9 -10 11 CFU/200ul.
4. 4. Use of a traditional Chinese medicine probiotic composition according to any one of claims 1 to 3 for the preparation of a medicament for the prevention and treatment of colorectal cancer, characterized in that said traditional Chinese medicine composition is administered simultaneously or sequentially with said bifidobacterium pseudolongum.
5. 5. The use according to claim 4, wherein the bifidobacterium pseudolongum is a live bacterium, a freeze-dried bacterium or a metabolite thereof.
6. 6. A formulation prepared from the traditional Chinese medicine probiotic composition according to any one of claims 1 to 3, characterized in that the formulation is a pill, a capsule, a fluid extract, a granule.
7. 7. Use of a formulation according to claim 6 for the manufacture of a medicament for the prevention and treatment of colorectal cancer.

Description

Traditional Chinese medicine probiotics composition for preventing and treating colorectal cancer and application thereof Technical Field The invention belongs to the field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine probiotic composition for preventing and treating colorectal cancer and application thereof. Background Colorectal cancer (colorectal cancer, CRC) remains a significant global health challenge, one of the most common malignancies, and the second leading cause of cancer-related mortality. Prognosis for CRC patients is highly correlated with clinical staging, with early and mid-stage CRC patients having a 5-year survival rate of 91% and 73%, respectively, whereas late stage disease patients have a 5-year survival rate of only 14%. Therefore, the CRC intervention gateway is moved forward, and the method has important significance for CRC prevention and control. The occurrence and development of CRC are closely related to various factors such as genetic factors, dietary structures, inflammatory reactions, intestinal flora imbalance and the like. Wherein chronic inflammation driven "inflammatory cancer transformation" is a key pathological evolution of CRC occurrence. Chronic inflammation can disrupt the intestinal epithelial barrier, accelerating the conversion of intestinal epithelial cells into tumor cells. At the same time, immune cells, including macrophages, are recruited to the gut where proinflammatory cytokines are released. This signal initiates a vicious circle of inflammation exacerbation, leading to epithelial barrier dysfunction and disruption of intestinal homeostasis. Research and statistical analysis indicate that long-term intestinal inflammation increases the risk of intestinal cancer by a factor of 6-8. In particular, chronic inflammation of the intestinal tract with dysplasia of the intestinal glands accelerates the progression of normal epithelial-adenoma-adenocarcinoma. In addition, inflammation accelerates the cancerous process associated with mutations in the APC gene. Thus, inhibiting inflammation-driven colorectal cancer transformation is an important strategy to reduce the incidence of CRC. Although studies have shown that non-steroidal anti-inflammatory drugs (NSAIDs), and cyclooxygenase-2 (COX-2) inhibitors can reduce the incidence of CRC by inhibiting inflammation, their use is limited by certain adverse effects. Therefore, finding a safer and more efficient CRC prevention and treatment strategy has important clinical significance. The abundant and long clinical history of traditional Chinese medicine provides valuable resources for determining effective treatment methods for a series of diseases. The pulsatilla root decoction (Baitouweng decoction, BTW) is a traditional Chinese medicine compound commonly used in clinic, and consists of pulsatilla root, ash bark, phellodendron bark and coptis root according to the ratio of 5:4:4:2. BTW has a variety of pharmacological actions including anti-inflammatory, antioxidant and autophagy enhancing activities. It has attracted increasing attention due to its remarkable clinical efficacy in inflammatory diseases of the intestinal tract. In addition, animal studies have shown that BTW can ameliorate DSS-induced colitis by modulating immune cells, modulating intestinal flora, etc., and exhibit therapeutic potential for CRC. However, the effect of BTW on CRC control remains to be elucidated. In recent years, numerous studies have shown that intestinal microbiota and its metabolites play a critical role in maintaining intestinal homeostasis, with deregulation being closely related to the pathogenesis of colitis and colorectal cancer. On the one hand, the regulation of intestinal flora is a key mechanism for the therapeutic effect of traditional Chinese medicine. On the other hand, intestinal microbiota can metabolize traditional Chinese medicine compounds, and the bioavailability and the overall curative effect of the intestinal microbiota are improved. However, current probiotic intervention protocols for CRC are still under investigation, and the specific effective strains and their combination with drugs are not well-defined. Therefore, a novel CRC prevention and treatment scheme based on BTW compound and combined with intestinal flora regulation is developed, and the method has important scientific significance and application value. Disclosure of Invention The invention aims to provide a traditional Chinese medicine probiotics composition for preventing and treating colorectal cancer and application thereof, so as to solve the problems that the colorectal cancer prevention and treatment means in the prior art are limited in curative effect, obvious in side effect and lack of traditional Chinese medicine-probiotics combined intervention scheme. The invention provides a traditional Chinese medicine probiotics composition, which consists of a traditional Chinese medicine composition